Immix Biopharma (IMMX) Competitors $1.80 -0.02 (-1.10%) (As of 10:22 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMMX vs. RAPT, BCAB, LABP, MCRB, ADAP, OPT, ADCT, EDIT, NBTX, and ZURAShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include RAPT Therapeutics (RAPT), BioAtla (BCAB), Landos Biopharma (LABP), Seres Therapeutics (MCRB), Adaptimmune Therapeutics (ADAP), Opthea (OPT), ADC Therapeutics (ADCT), Editas Medicine (EDIT), Nanobiotix (NBTX), and Zura Bio (ZURA). These companies are all part of the "medical" sector. Immix Biopharma vs. RAPT Therapeutics BioAtla Landos Biopharma Seres Therapeutics Adaptimmune Therapeutics Opthea ADC Therapeutics Editas Medicine Nanobiotix Zura Bio RAPT Therapeutics (NASDAQ:RAPT) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation. Do analysts recommend RAPT or IMMX? RAPT Therapeutics currently has a consensus price target of $9.50, suggesting a potential upside of 835.96%. Immix Biopharma has a consensus price target of $7.00, suggesting a potential upside of 288.89%. Given RAPT Therapeutics' higher possible upside, analysts plainly believe RAPT Therapeutics is more favorable than Immix Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RAPT Therapeutics 1 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.08Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor RAPT or IMMX? RAPT Therapeutics received 80 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 63.12% of users gave RAPT Therapeutics an outperform vote. CompanyUnderperformOutperformRAPT TherapeuticsOutperform Votes8963.12% Underperform Votes5236.88% Immix BiopharmaOutperform Votes9100.00% Underperform VotesNo Votes Which has more risk and volatility, RAPT or IMMX? RAPT Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Is RAPT or IMMX more profitable? RAPT Therapeutics' return on equity of -89.10% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets RAPT TherapeuticsN/A -89.10% -76.13% Immix Biopharma N/A -102.68%-80.89% Which has higher earnings & valuation, RAPT or IMMX? Immix Biopharma has lower revenue, but higher earnings than RAPT Therapeutics. Immix Biopharma is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRAPT Therapeutics$1.53M23.19-$116.80M-$2.77-0.37Immix BiopharmaN/AN/A-$15.43M-$0.85-2.12 Does the media prefer RAPT or IMMX? In the previous week, RAPT Therapeutics had 9 more articles in the media than Immix Biopharma. MarketBeat recorded 9 mentions for RAPT Therapeutics and 0 mentions for Immix Biopharma. RAPT Therapeutics' average media sentiment score of 0.52 beat Immix Biopharma's score of -3.00 indicating that RAPT Therapeutics is being referred to more favorably in the media. Company Overall Sentiment RAPT Therapeutics Positive Immix Biopharma Very Negative Do institutionals & insiders hold more shares of RAPT or IMMX? 99.1% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 6.6% of RAPT Therapeutics shares are owned by insiders. Comparatively, 48.9% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryRAPT Therapeutics beats Immix Biopharma on 11 of the 16 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.52M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-2.124.9789.5613.60Price / SalesN/A371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book2.8110.306.976.33Net Income-$15.43M$153.61M$119.04M$225.93M7 Day Performance11.11%-1.73%-1.78%-0.96%1 Month Performance12.50%-7.26%-3.59%1.06%1 Year Performance-57.04%31.10%31.64%26.59% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma2.2959 of 5 stars$1.80-1.1%$7.00+288.9%-58.7%$49.52MN/A-2.129Negative NewsRAPTRAPT Therapeutics4.5983 of 5 stars$1.02-5.1%$9.50+836.0%-92.3%$35.48M$1.53M0.0080BCABBioAtla2.8165 of 5 stars$1.44-2.7%$6.00+316.6%-11.4%$69.63M$250,000.000.0060Short Interest ↓LABPLandos BiopharmaN/A$22.93+0.6%$20.42-10.9%+486.4%$71.77M$18M-5.7519High Trading VolumeMCRBSeres Therapeutics3.6801 of 5 stars$0.85+4.2%$5.08+499.7%-16.1%$144.74M$126.32M0.00233Analyst UpgradeADAPAdaptimmune Therapeutics2.1006 of 5 stars$0.65-2.6%$3.16+388.4%+54.9%$165.68M$60.28M0.00449Analyst RevisionOPTOpthea2.074 of 5 stars$3.32+1.2%$12.00+261.4%+72.4%$193.89M$120,000.000.008ADCTADC Therapeutics2.8921 of 5 stars$2.00+1.0%$8.25+312.5%+177.9%$193.38M$69.56M0.00310Positive NewsEDITEditas Medicine4.6915 of 5 stars$2.34-2.9%$9.08+288.2%-77.8%$193.17M$78.12M-0.94230Short Interest ↓NBTXNanobiotix2.3432 of 5 stars$4.07+7.7%$11.50+182.7%-33.5%$191.75M$39.18M0.00100Positive NewsZURAZura Bio3.9055 of 5 stars$2.92+0.7%$15.80+441.1%-35.1%$190.65MN/A0.003Analyst Forecast Related Companies and Tools Related Companies RAPT Therapeutics Competitors BioAtla Competitors Landos Biopharma Competitors Seres Therapeutics Competitors Adaptimmune Therapeutics Competitors Opthea Competitors ADC Therapeutics Competitors Editas Medicine Competitors Nanobiotix Competitors Zura Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMMX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
